MARKET

IBIO

IBIO

IBIO
AMEX

Real-time Quotes | Nasdaq Last Sale

2.015
-0.005
-0.25%
Opening 13:05 02/24 EST
OPEN
2.050
PREV CLOSE
2.020
HIGH
2.070
LOW
2.000
VOLUME
3.38M
TURNOVER
--
52 WEEK HIGH
7.45
52 WEEK LOW
0.2810
MARKET CAP
435.26M
P/E (TTM)
-11.0471
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
iBio Inc. stock falls Tuesday, underperforms market
Shares of iBio Inc. slid 1.46% to $2.02 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial...
marketwatch.com · 20h ago
iBio Inc. stock rises Monday, outperforms market
marketwatch.com · 1d ago
Human Papillomavirus Protein E7 Market Global Revenue, Trends, Growth, Share, Size and Forecast 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 06:21:10 / Comserve Inc. / -- Human Papillomavirus Protein E7 market is segmented by Type, and by Application. Players,...
Comserve · 2d ago
Plant Based Vaccines Market to Witness Astonishing Growth With Vital Key Players | Medicago Inc, iBio Inc
Feb 22, 2021 (WiredRelease via Comtex) -- A consciously conceived and designed business intelligence report titled Global Plant Based Vaccines market 2021 by...
marketresearch.biz · 2d ago
Alpha Galactosidase A Market Global Market Size, Share, Development, Growth and Demand Forecast, 2020-2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 00:42:38 / Comserve Inc. / -- Alpha Galactosidase A market is segmented by Type, and by Application. Players, stakeholders, and...
Comserve · 2d ago
iBio Inc. stock underperforms Friday when compared to competitors
Shares of iBio Inc. slid 2.93% to $1.99 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite...
marketwatch.com · 4d ago
iBio Inc. stock remains steady Thursday, still outperforms market
Shares of iBio Inc. were unchanged Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index...
marketwatch.com · 5d ago
Global Alpha Galactosidase A Market Size 2021 Analysis by Industry Share, Forthcoming Developments, End-User Demand, Size Estimation, Growth Factors, Overview, and Forecast Report till 2027
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Alpha Galactosidase A Market”...
The Express Wire · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBIO. Analyze the recent business situations of IBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IBIO stock price target is 2.500 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 332.24K
% Owned: 0.15%
Shares Outstanding: 216.01M
TypeInstitutionsShares
Increased
4
14.06K
New
2
19.83K
Decreased
3
6.98K
Sold Out
1
250
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.35%
Pharmaceuticals & Medical Research
+1.20%
Key Executives
Chairman/President/Chief Executive Officer/Director
Thomas Isett
Chief Financial Officer/Chief Accounting Officer
John Delta
Chief Operating Officer
Randy Maddux
Chief Scientific Officer
Martin Brenner
Treasurer/Secretary/Director
Robert Kay
Independent Director
Linda Armstrong
Independent Director
Glenn Chang
Independent Director
Seymour Flug
Independent Director
James Hill
Independent Director
Alexandra Kropotova
Independent Director
John McKey
Independent Director
Gary Sender
  • Dividends
  • Splits
  • Insider Activity
No Data
About IBIO
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.